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Abstract: The neuropeptide pituitary adenylate cyclase activating polypeptide (PACAP) has two
active forms, PACAP1-27 and PACAP1-38. Among the well-established actions are PACAP’s
neurotrophic and neuroprotective effects, which have also been proven in models of different
retinopathies. The route of delivery is usually intravitreal in studies proving PACAP’s retinoprotective
effects. Recently, we have shown that PACAP1-27 delivered as eye drops in benzalkonium-chloride
was able to cross the ocular barriers and exert retinoprotection in ischemia. Since PACAP1-38
is the dominant form of the naturally occurring PACAP, our aim was to investigate whether the
longer form is also able to cross the barriers and exert protective effects in permanent bilateral
common carotid artery occlusion (BCCAO), a model of retinal hypoperfusion. Our results show that
radioactive PACAP1-38 eye drops could effectively pass through the ocular barriers to reach the
retina. Routine histological analysis and immunohistochemical evaluation of the Müller glial cells
revealed that PACAP1-38 exerted retinoprotective effects. PACAP1-38 attenuated the damage caused
by hypoperfusion, apparent in almost all retinal layers, and it decreased the glial cell overactivation.
Overall, our results confirm that PACAP1-38 given in the form of eye drops is a novel protective
therapeutic approach to treat retinal diseases.
Keywords: eye drops; PACAP; ischemic retinopathy; carotid artery occlusion; neuroprotection
1. Introduction
Pituitary adenylate cyclase activating polypeptide (PACAP) is a well-known neuropeptide that
acts on G protein-coupled receptors, namely PAC1, and VPAC1 as well as VPAC2 receptors. PACAP
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exists in two biologically active forms, PACAP1-27 and PACAP1-38. PACAP has a wide variety of
diverse biological effects in different cells and tissues, from thermoregulatory effects [1], actions on
cardiac excitability [2], thyroid gland functions [3], chondrogenesis [4] and muscle contraction [5].
Among the well-established and most intensively studied actions are PACAP’s neurotrophic and
neuroprotective effects. PACAP has been shown to protect neurons against various noxious stimuli
in vitro and in vivo [6–8] For example, PACAP is protective in traumatic brain [9] and spinal cord
injury [10], in global and focal cerebral ischemia [6], in models of Huntington’s disease [11], and in
Parkinson’s disease [12–14].
PACAP’s trophic and protective effects in the retina are also well-established and confirmed by
several research groups. PACAP influences the development of the retina [15], and protects against
several in vitro and in vivo retinal injuries [16–19]. In vitro, the peptide has been shown to protect
whole retinal tissue cultures [20] and cell cultures from various cell types, including pigment epithelial
cells [21,22] and retinal ganglion cells [23]. In vivo, PACAP is protective against NMDA-, glutamate-
and kainate-induced retinal excitotoxicity [24–26], optic nerve transection [27], UV-induced retinal
damage [28], diabetic retinopathy [29,30], retinopathy of prematurity [31] and ischemia-induced
injury [32–34].
In vivo studies apply PACAP through intravitreal injection, whereby the peptide is injected into
the vitreous body and reaches the retina by diffusion through the vitreous and layers of the retina
itself. This route of administration of therapeutic agents is a common practice in the treatment of
several retinopathies, including vascular endothelial growth factor (VEGF) antagonists in age-related
macular degeneration and diabetic retinopathy. However, delivery of therapeutic substances in eye
drops is more convenient and causes fewer side effects. The main problem with eye drops is that
most substances do not cross the ocular barriers to reach a suitable therapeutic concentration in the
retina. We have recently provided evidence that PACAP1-27, the shorter form of PACAP, crosses the
ocular barriers and reaches the retina in an amount sufficient to exert retinal protection in a model
of retinal ischemia [35]. In this study, we investigated several vehicles to deliver PACAP1-27 as eye
drops, and found that benzalkonium-chloride (benzalkonium solution for ophthalmic use -SOCB)
was the most effective vehicle. Using PACAP1-27 in benzalkonium solution eye drops in ischemic
retinal injury, we demonstrated less pronounced thinning of the retinal layers, decreased neuronal loss,
decreased ischemia-induced glial activation, reduced cytokine levels and an activation of protective
anti-apoptotic molecules [35].
In our first study using PACAP in eye drops, we chose PACAP1-27 for its better lipid solubility,
stability and under the assumption that it crossed ocular barriers more easily since it is 11 amino acids
shorter than PACAP1-38 [36]. From the two biologically active forms of the peptide, PACAP1-38 is the
more common form, comprising about 90% of PACAP in the mammalian body. They bind to the same
receptors and have the same or similar actions in most models [37]. In models and experimental setups,
where the two main forms of the peptide exert similar actions, PACAP1-38 is usually more potent
than PACAP1-27, mainly explained with the stronger receptor-binding capacity of PACAP1-38 [38,39].
However, several differences also exist between the two peptides in some other models, including
opposite effects on luteinizing hormone (LH) secretion [40]. Therefore, the aim of the present study
was to investigate whether PACAP1-38, the longer form of the peptide, is also able to cross the ocular
barriers and exert retinoprotective effects in permanent bilateral common carotid artery occlusion
(BCCAO), a model of retinal hypoperfusion.
2. Results
2.1. Retina Morphology and Morphometry
BCCAO resulted in severely reduced thickness of retinal layers two weeks after ligation, compared
to sham retinas (Figure 1A,C). PACAP1-38 alone in sham animals did not result in changes in any of
the retinal layers (Figure 1A,B). PACAP1-38 dissolved in solutio ophthalmica cum benzalkonio (briefly,
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benzalkonium) led to significant protection in the retina in BCCAO-lesioned retinas (Figure 1D); retinas
treated with PACAP1-38 eye drops had preserved structure compared to control retinas (Figure 1D).
OLM–ILM (outer limiting membrane–inner limiting membrane) distance was reduced by 49.7%
(p < 0.001) in BCCAO retinas compared to sham controls, but it was only 40.6% (p < 0.001) in the eyes
treated with PACAP1-38 eye drops. A protection to a similar degree was found in the inner nuclear
layer (INL) (BCCAO: 38.5%, PACAP1-38: 30.5%; p < 0.001), and inner plexiform layer (IPL) (BCCAO:
64.8%, PACAP1-38: 38.2%; p < 0.05), while no statistically significant attenuation of the damage was
observed in the outer nuclear layer (ONL) (BCCAO: 36.5%, PACAP1-38: 37.7%) or outer plexiform
layer (OPL) (BCCAO: 53.0%, PACAP1-38: 48.2%) (Figure 2). The number of cells in the ganglion
cell layer (GCL) was significantly decreased after BCCAO by 52.4% (p < 0.05) and was significantly
ameliorated by PACAP1-38 eye drops (decreased by 25.9%; p < 0.05) (Figure 3).
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Figure 1. Light microphotographs of retinal sections. Retinal tissue from bilateral common carotid 
artery occlusion (BCCAO) (n = 9) (C) showed severe degeneration compared to sham (n = 3) (A) and 
sham + PACAP1-38 eye drops retinas (n = 3) (B); The retinal layers of BCCAO rats following 
treatment with eye drops containing PACAP1-38 eye drops (n = 9) (D) showed only mild 
degeneration. (Scale bar: 50 µm). Abbreviations: ONL: outer nuclear layer, OPL: outer plexiform 
layer, INL: inner nuclear layer, IPL: inner plexiform layer, GCL: ganglion cell layer. 
 
Figure 2. Quantification of retinal layers in sham (n = 3 sham, n = 3 sham + PACAP1-38 eye drops) 
and BCCAO (n = 9 BCCAO, n = 9 BCCAO + PACAP1-38 eye drops) animals: the right eye was treated 
with PACAP1-38 eye drops dissolved benzalkonium solution, the left eye served as a control 
receiving only benzalkonium solution. Comparison of retinal layers in sham animals with control, 
BCCAO rats and those receiving PACAP1-38 eye drops after carotid occlusion. Abbreviations: OLM, 
outer limiting membrane; ILM, inner limiting membrane; ONL, outer nuclear layer; OPL, outer 
plexiform layer; INL, inner nuclear layer; IPL, inner plexiform layer. Morphometric analysis showed 
that treatment with eye drops improves the structure of all the retinal layers (except ONL and OPL). 
Data are expressed as mean ± SEM. Statistical significance (** p < 0.001 vs. sham retinas, $$ p < 0.001 vs. 
sham + PACAP1-38 retinas, # p < 0.05; ## p < 0.001 vs. BCCAO retinas) was calculated by two-way 
ANOVA followed by Fischer’s post hoc test. 
Figure 1. Light microphotographs of retinal sections. Retinal tissue from bilateral common carotid
artery occlusion (BCCAO) (n = 9) (C) showed severe degeneration compared to sham (n = 3) (A) and
sham + PACAP1-38 eye drops retinas (n = 3) (B); The retinal layers of BCCAO rats following treatment
with eye drops containing PACAP1-38 eye drops (n = 9) (D) showed only mild d generation. (Scale
bar: 50 µm). Abbreviations: ONL: outer nuclear layer, OPL: outer plexiform layer, INL: inner nuclear
layer, IPL: inner plexiform layer, GCL: ganglion cell layer.
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Figure 2. Quantification of retinal layers in sha (n = 3 sham, n = 3 ham + PACAP1-38 eye drops) and
BCCAO (n = 9 B CAO, n = 9 BCCAO + PACAP1-38 eye drops) animals: th right eye was treated
with PACAP1-38 eye drops dissolved benzalkonium solution, the left eye served as a control receiving
only benzalkonium solution. Comparison of retinal layers in sham animals with control, BCCAO rats
and those receiving PACAP1-38 eye drops after carotid occlusion. Abbreviatio s: OLM, outer limiting
membrane; ILM, inner l miting memb an ; ONL, o ter nucl ar layer; OPL, ou er plexiform layer; INL,
inner nuclear layer; IPL, inner plexiform layer. Morphometric analysis showed that treatment with
eye drops improves the structure of all the retinal layers (except ONL and OPL). Data are expressed as
mean ± SEM. Statistical significance (** p < 0.001 vs. sham retinas, $$ p < 0.001 vs. sham + PACAP1-38
retinas, # p < 0.05; ## p < 0.001 vs. BCCAO retinas) was calculated by two-way ANOVA followed by
Fischer’s post hoc test.
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ANOVA followed by Fischer’s post hoc test.
2.2. PACAP1-38 Uptake af er Ocular Administratio
An amount of 1 × 106 counts per minute (cpm) of radioactively labeled PACAP1-38 was
administered ocularly to male CD-1 mice. Mice were sacrificed at time points b twe n 5 and 120 min
post administration. The eye was dissected into the cornea, retina, and vitreous humor, and the brain
and blood were collected. Levels of radioactively labeled PACAP1-38 were measured in each tissue
for this analysis. Transp rt of PACAP1-38 occurred rapidly as detection of radioactivity was present
in the eye, the brain, nd the serum five minutes r appl cation. PACAP1-38 displayed increasing
transport across the cornea over the time course of the study (Figure 4). The vitreous body showed
a similar profile to the cornea (Figure 4C). In the retina (Figure 4B), PACAP1-38 uptake increased to
30 min and plateaued. PACAP1-38 was detected after 5 min in the whole brain (Figure 4D) and levels
remained stable throughout the observation time. PACAP1-38 showed increased clearance into the
blood stream after 120 min (Figure 4E).
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Figure 4. Distribution of 125I-PACAP1-38 after ocular administration. An amount of 1 × 106 counts per
minute (cpm) of radioactively labeled PACAP1-38 was administered ocularly to male CD-1 mice. The
appearance of 125I-labeled PACAP1-38 in the cornea (A); retina (B); vitreous humor (C); whole brain
(D); and serum (E) was measured t 5, 0, 60, and 120 min post application. Values are expressed as
mean ± SEM for an n = 3 mice/time point.
2.3. PACAP1-38 Stability after Ocular Administration
To determine the extent to which the radioactivity observed in the regions of the eye, brain,
and serum after ocular administration of 125I-PACAP1-38 accurately represents the presence of the
administered protein, we performed an acid precipitation on the tissue. This was completed at 5 and
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60 min post application. The radioactivity of each sample after precipitation is reported as a percentage
of a matched processing control (Table 1). No statistical differences were observed between the two
time points (p > 0.05 by two-way analysis of variance) in any of the samples. In the eye, PACAP1-38
is about 50% intact, while in the brain the levels are higher (10 min: 104.71 ± 17.72; 60 min: 75.09 ±
41.13). This indicates that ocularly administered 125I-PACAP1-38 reaches all tissues intact and then
degradation occurs. We can postulate that the brain has fewer degrading enzymes than the eye or the
blood. In the serum, ocularly administered 125I-PACAP1-38 is almost completely degraded by 5 min.
This is not surprising because the half-life of PACAP injected into mice and humans is between 2 and
10 min due to enzymatic degradation. This indicates that we will not obtain off-target effects from
PACAP1-38 as it degrades rapidly in the blood stream.
Table 1. Acid precipitation of radioactivity extracted from eyes, brain, and serum after ocular
administration of PACAP1-38 labeled with radioactive iodine. Percentage of acid precipitation for eyes,
whole brain, and serum taken at 5 and 60 min post ocular administration of 125I-PACAP1-38. Values
are corrected for degradation that occurred during processing. Results are means ± SEM from an n = 3
at each time point.
Region of Interest 10 min 60 min
Eye 52.73 ± 2.35 48.24 ± 3.39
Whole Brain 104.71 ± 17.72 75.09 ± 41.13
Serum 25.57 ± 25.57 0 ± 0
2.4. Immunohistochemical Analysis of Retinal Glial Cell Activation
Müller glial cells are specific glial cells of the retina. Their cell bodies are found in the INL,
and their endfeet extend between OLM and ILM. Glial fibrillary acidic protein (GFAP) filaments are
intermediate filaments expressed mainly by astrocytes and ependymal cells in the central nervous
system, and are also present in the inner part of the Müller glial cells (Figure 5A,B) [41]. GFAP signal
shows upregulation after various injuries, showing over-activation of the Müller glial cells. Similar to
earlier observations, we could detect significant upregulation of the GFAP immunostaining (p < 0.001)
in the retina sections after BCCAO (Figure 5C). Similar to our recent study, an immunopositive signal
was observed not only in the inner endfeet, but also in the entire cell extending from the OLM to
ILM (Figure 5C). PACAP1-38 eye drops significantly (p < 0.05) attenuated the GFAP upregulation
(Figure 5D).
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of Müller cells. Retinal degeneration caus d by BCCAO (C) showed significant upregulation of
immunoreactivity (p < 0.001). After PACAP1-38 ey drops (D), the immunopositivity was significantly
reduced (p < 0.05). Abbreviations: ONL, outer nuclear layer; INL, inner nuclear layer; GCL, ganglion
cell layer; ILM, inner limiting membrane; PI, propidium iodide; GFAP, glial fibrillary acidic protein.
(Scale bar: 50 µm).
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3. Discussion
In the present study, we demonstrated that PACAP1-38, delivered as an eye drop, effectively
counteracted the deleterious effects of rat retinal ischemia induced by permanent ligation of both
carotid arteries. The present results are in accordance with our recent observations with PACAP1-27 eye
drops [35]. In this recent study, we confirmed that PACAP1-27, dissolved in benzalkonium-chloride,
passes through the mouse ocular barriers from the corneal surface to the retina, and ameliorates the
retinal lesion. Our present results show similar actions of PACAP1-38: the thinning of the retinal layers
as well as the reduction of the cells in the ganglion cell layer was not as expressed after PACAP1-38
eye drops treatment as in the control animals. Furthermore, the over-activation of the Müller glial cells
was attenuated. Studying the passage through the ocular barriers confirmed that PACAP could be
detected in the cornea, vitreous body and then in the retina in a concentration high enough to reach
retinal protection. PACAP could also be detected in the serum and brain, but levels were negligible in
comparison to ocular levels.
Our present study, together with the previous study on PACAP1-27, highlights the potential
therapeutic use of PACAP in the form of eye drops to treat retinal diseases. The novelty of our present
results is that PACAP1-38, the most commonly occurring form of the peptide, exerts a retinoprotective
effect similarly to PACAP1-27. Although most actions of PACAP1-27 and PACAP1-38 are similar or
the same, several differences are also known. In most studies, PACAP1-27 binds to the receptors with
less affinity, leading to less well-pronounced effects at the same concentration as PACAP1-38 [6,36].
The metabolic stability is also different: while PACAP1-38 is rapidly degraded in the serum by
dipeptidyl-peptidase, accounting for the short half-life of the peptide, PACAP1-27 is more stable due to
the resistance against dipeptidyl-peptidase reaction [36]. Penetration through membranes also differs:
it has been demonstrated in a recent study that cell-penetrating PACAP1-38, in high concentrations,
reduced viability of retinoblastoma cells, but PACAP1-27 had negligible effects [42]. Even opposite
actions have been described: intracerebroventricular administration of PACAP1-38 led to an inhibition
of the LH surge, while opposite reaction was observed after PACAP1-27 injection [40]. In the present
study, we found that the retinoprotective efficacy of PACAP1-38 and PACAP1-27 were the same, and
they both were able to cross the ocular barriers given in the form of eye drops.
In the retina, we demonstrated that intravitreal injection of PACAP1-27 and 1-38 led to the same
degree of retinoprotection in monosodium glutamate-induced excitotoxic lesions [43]. In contrast, the
receptor antagonists PACAP6-38 and PACAP6-27 further increased the excitotoxic damage, indicating
the protective effect of the endogenous peptide [43], later confirmed in PACAP-deficient mice [44].
Peptides in the same peptide family as PACAP (VIP/secretin/glucagon peptide family) do not have
such marked protective effects in the retina. VIP, the peptide with the closest structural similarity
to PACAP, led to a neuroprotective effect in ischemic retinopathy at concentrations ten times higher
than required for PACAP to exert the same degree of protection [45]. In a recent study, we compared
the retinoprotective efficacy of glucagon and secretin, two other peptides from the same peptide
family: they do not exert protective effects in ischemic retinal lesion, similarly to several other shorter
fragments of PACAP tested [34].
PACAP eye drops have been used in previous experiments to treat corneal diseases. Nakamachi
and coworkers [46] have recently described that PACAP eye drops stimulated tear secretion, increased
cAMP release and aquaporin expression in the infraorbital lacrimal gland in mice and suppressed
corneal keratinization in PACAP null animals. PACAP eye drops have also been shown to enhance
corneal wound healing [47] and accelerate regeneration of corneal nerve endings [48]. However, our
studies are the first to show that PACAP administered as eye drops can reach the retina and exert
protective effects.
The protective mechanism is supposedly similar to what we have previously found with
PACAP1-27 eye drops and with intravitreal injections of PACAP in different retinal injury models [17].
We have described that PACAP1-27 eye drops decreased retinal inflammatory cytokine expression
and increased the protective Akt and ERK1/2 in hypoperfused retinas [35]. In other studies, we have
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provided evidence for the anti-apoptotic effects of the peptide in retinal lesions, including attenuation
of caspases, JNK, p38, apoptosis-inducing factor, cytochrome c release, while increasing 14-3-3 protein
expression and ERK, Bcl-XL and bad phosphorylation [49–51]. In summary, our present study confirms
the therapeutic potential of PACAP eye drops in ischemic retinal lesion and provides further evidence
for the protective efficacy of PACAP in neuronal ischemia [52–54].
4. Materials and Methods
4.1. Surgery and PACAP1-38 in Benzalkonium Solution Treatment
Wistar rats (n = 20:n = 12 for histological analysis, n = 8 for immunohistochemical analysis)
weighing 250–300 g were subjected to permanent ligation of both common carotid arteries. The
animals were bred and kept in the Animal Facility of the University of Pecs, Medical School. They were
fed and watered ad libitum, under light/dark cycles of 12/12 h. All procedures were in accordance
with institutional guidelines (ethical permission No: BA02/2000-31/2011, University of Pecs). Under
isoflurane anesthesia, both common carotid arteries were exposed through a midline cervical incision
and ligated with a 3-0 filament. Directly after the operation within 1 min, the right eye was treated
with PACAP1-38 eye drops (1 µg/drop) (PACAP was synthesized at the Department of Medical
Chemistry, University of Szeged, Szeged, Hungary). The vehicle used was benzalkonium-chloride
in a concentration of 0.005%, as it was the most effective vehicle to achieve neuroprotection with
PACAP1-27 eye drops, proven in our previous study [35]. The left eye served as a control, treated only
with the vehicle. A group of animals served as the sham-operated group that underwent anesthesia
and all steps of the surgical procedure except ligation of the carotid arteries. Rats were treated twice a
day with one drop, for 5 consecutive days [35].
4.2. Histological Analysis of PACAP1-38 Eye Drops
Rats (n = 3 sham, n = 3 sham + PACAP1-38, n = 9 BCCAO, n = 9 BCCAO + PACAP1-38 retinas)
were sacrificed with an overdose of anesthetic 2 weeks after BCCAO and eyes were processed for
histological analysis. Histological analysis was performed as described previously [35]. Briefly,
removed retinas were dissected in phosphate buffered saline (PBS), fixed in 4% paraformaldehyde
dissolved in 0.1 M phosphate buffer (PB), embedded in Durcupan ACM resin, and two-µm-thick
sections were stained with toluidine blue (Sigma, Budapest, Hungary). Four tissue blocks obtained
from at least three rats were prepared and central retinal areas within 1 mm from the optic nerve were
used (n = 5 measurements from one tissue block). The following parameters were measured on digital
photographs taken with a Nikon Eclipse camera using the Spot program: cross-section from the outer
limiting membrane (OLM) to the inner limiting membrane (ILM), and width of all retinal layers (outer
nuclear layer-ONL, outer plexiform layer-OPL, inner nuclear layer-INL, inner plexiform layer-IPL).
We also counted the number of cells in the ganglion cell layer (GCL). Results are presented as mean
± SEM. Statistical comparisons were made using the two-way ANOVA followed by Fischer’s post
hoc analysis.
4.3. Analysis of the Passage of PACAP1-38 Eye Drops through the Ocular Barriers
PACAP1-38 was labeled with 125I using the lactoperoxidase method, as previously described
with PACAP1-27 [35]. Briefly, 10 µg of PACAP1-38 (dissolved in 0.25 M chloride free phosphate buffer)
was mixed with 30 µL of 0.4 M Na acetate (pH 5.6), 10 µL of lactoperoxidase (10 µg/mL dissolved
in 0.1 M Na acetate pH 5.6), and 2 mCi of 125I. The reaction was started by adding 10 µL 30% H2O2
solution (prepared by adding 2 µL H2O2 in 30 ml deionized (dI) H2O). Ten minutes later, an additional
10 µL of the 30% H2O2 solution was added and the reaction was allowed to progress 10 min more.
At the end of this second 10 min incubation, the reaction solution was purified with high performance
liquid chromatography (HPLC, Shimadzu USA Manufacturing Inc., Columbia, MD, USA) using a C18
column (P.J. Cobert Associates, Inc., St. Louis, MO, USA).
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The PACAP1-38 fraction collected from the HPLC was evaporated overnight in a fume hood
using constant airflow to evaporate off the 0.1% trifluoroacetic acid in methanol solution that the
fraction was collected in. The dried fraction was resuspended in 1% BSA Lactated Ringers’ solution
and an acid precipitation was completed to assess the purity of the PACAP1-38 fraction. The acid
precipitation was completed with 15% trichloroacetic acid. The percent of radioactivity precipitated
was calculated using the following formula: 100 × [(CPMpellet)/(CPMpellet + CPMsupernatant)].
Only fractions that showed >90% activity in the precipitate were used in the experiment. A 1 × 106
cpm solution was prepared in a 10 µL volume of benzalkonium-chloride. A 10 µL drop was placed on
each eye delivering 1 × 106 cpm per eye. The two eyes were pooled together for analysis.
An amount of 1 × 106 cpm/eye in benzalkonium-chloride of radioactively labeled PACAP1-38
was administered once ocularly to male CD-1 mice. Mice were sacrificed at time points between 5 and
120 min post administration (5, 30, 60, and 120 min). The eye was dissected into the cornea, retina,
and vitreous humor, and the brain and blood were collected from the carotid artery, and the eyes and
whole brain removed. Levels of radioactively labeled PACAP1-38 were measured in each tissue for
this analysis. Mice (n = 3) were used at each time point. The collected whole blood was allowed to
clot at room temperature, centrifuged at 5400× g for 10 min at 4 ◦C, and 50 µL of the resulting serum
was removed for use. The whole brain was collected and the eye dissected into the cornea, retina, and
vitreous humor. The level of radioactivity in each of the regions and the serum was measured in a
Wizard2 Automatic Gamma Counter (PerkinElmer, Waltham, MA, USA). The percentage of injected
dose present in a milliliter of serum (%Inj/mL) and the percentage of the injected dose taken up per
gram of tissue (%Inj/g) was calculated as previously described [55,56].
4.4. In Vivo Stability of 125I-PACAP1-38
Mice were anesthetized with urethane and administered PACAP1-38 as an eye drop
(1 × 106 cpm/eye in benzalkonium-chloride). Serum, whole brain, and eyes were collected 10 or
60 min after the eye drops were administered. The whole brain and eyes were washed in ice-cold PBS.
Blood was allowed to clot, centrifuged at 5400× g for 10 min, and 50 µL of the serum obtained was
added to 200 µL of 1% BSA in Lactated Ringers’ (LR) solution. This mixture was added to 250 µL
of 30% trichloroacetic acid, vortexed, and centrifuged for 10 min at 5400× g. Brains and eyes were
homogenized separately in 0.5 mL of 1% BSA-LR with a bead beater for 30 s at 4800 rpm × 2 on ice.
Samples were transferred to a microfuge tube and centrifuged at 10,000× g for 20 min and a portion
of the resulting supernatant added to an equal volume of 30% trichloroacetic acid, vortexed, and
centrifuged at 5400× g for 10 min. Resulting supernatant (S) and precipitate (P) from the serum, whole
brain, and eyes were counted separately and the percent of radioactivity which could be precipitated
with acid (% Precip) was calculated using: % Precip = 100(P)/(S + P).
To correct for any degradation that might have occurred during the processing for acid
precipitation, we added 125I-PACAP1-38 to non-radioactive arterial whole blood, whole brain, and
eyes, and processed as above. Biological samples were corrected for degradation during processing by
dividing their values by the processing control values.
4.5. Measurement of Glial Fibrillary Acidic Protein (GFAP) Activity in the Müller Glial Cells
For immunohistochemical analysis, 2 weeks after the induction of ischemia, animals (n = 4 sham,
n = 4 sham + PACAP1-38 and n = 4 BCCAO; n = 4 BCCAO + PACAP1-38 retinas) were sacrificed with
120 mg/kg pentobarbital (Nembutal, Sanofi-Phylaxia, Budapest, Hungary). The eyes were dissected
thereafter in ice-cold PBS and fixed in 4% paraformaldehyde dissolved in 0.1 M PB (pH 7.4) for 4 h at
room temperature, similarly to earlier descriptions [35]. Retinas were washed in 0.1 M PB (6 × 10 min)
and cryoprotected in 10% and 20% sucrose for 1 h, followed by 30% sucrose in PBS (Sigma, Budapest,
Hungary) overnight at 4 ◦C. Tissues were embedded in tissue freezing medium for cryostat sectioning
(Cryomatrix, Shandon, Waltham, MA, USA). Ten–twelve µm setions were made with a cryostat (Leica,
Nussloch, Germany). Central retinal areas within 2 mm from the optic nerve head were used for
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immunohistochemical analysis. Retina sections were mounted on chrome–alum–gelatin coated slides
and stored at−20 ◦C until use. Sections were rinsed in PBS, permeabilized by incubation for 6 × 5 min
in 0.1% Triton X-100 (Sigma, Budapest, Hungary) in PBS and incubated with 3% normal donkey serum
and 0.1% Na-azide in PBS for 1 h to minimize nonspecific labeling. Incubation with the primary
polyclonal antibody, anti-GFAP, lasted overnight at 4 ◦C (rabbit anti-GFAP 1:1000, Sigma), in 1%
donkey serum (Sigma). After being washed in PBS six times, incubation in the secondary fluorescent
anti-rabbit antibody Alexa Fluor 488 (donkey anti-rabbit, 1:200, Life Technologies, Budapest, Hungary)
followed for 2 h at room temperature in the dark. After washing in PBS, propidium iodide (PI,
1:500, Sigma) was used to detect the nuclear components. After three washes in PBS, sections were
coverslipped using Fluoroshield (Sigma). Primary antibodies were omitted for control experiments,
resulting in no specific staining. Digital photographs were taken with a Nikon Eclipse Ci fluorescence
microscope. Photographs were further processed with the Adobe Photoshop CS6 program (version
13.0 X64, San Jose, CA, USA). Images were adjusted for contrast only; they were aligned, arranged and
labeled by using the functions of the above program. The examiner evaluating the images was not
aware of the experimental groups.
4.6. Statistical Analysis
Statistical comparisons were made using the two-way ANOVA followed by Fischer’s post
hoc analysis.
5. Conclusions
Based on the present results, we conclude that PACAP1-38, delivered as an eye drop, effectively
ameliorates the effects of rat chronic retinal ischemia.
Acknowledgments: Supported by grants from the National Scientific Research Fund (OTKA K104984),
GINOP-2.3.2-15- 2016-00050 “PEPSYS”, the National Research, Development and Innovation Fund K119759,
MTA-TKI of the Hungarian Academy of Sciences, PTE AOK KA Research Grant, Bolyai Scholarship, National Brain
Research Program (KTIA_13_NAP-A-III/5), TAMOP 4.2.4.A/2-11-1-2012-0001 “National Excellence Program”,
The UNKP-16-4-IV, UNKP-16-4-III, UNKP-16-4-I, New National Excellence Program of the Ministry of Human
Capacites, and Centre for Neuroscience, University of Pecs. The present scientific contribution is dedicated to the
650th anniversary of the foundation of the University of Pécs, Hungary.
Author Contributions: Dora Werling, Tamas Atlasz, Dora Reglodi conceived and designed the experiments;
Dora Werling, Tamas Atlasz, Therese S. Salameh, William A. Banks, Dora Reglodi, Alexandra Vaczy,
Edina Szabo, Timea Kvarik, Flora Mayer, Rita Varga performed the experiments; Dora Werling, Tamas Atlasz,
Laszlo Akos Kovacs, Timea Kvarik analyzed the data; Andrea Tamas, Zsolt Biro and Gabor Toth contributed
reagents/materials/analysis tools; Dora Werling, Tamas Atlasz, Dora Reglodi, William A. Banks and
Therese S. Salameh wrote the paper.
Conflicts of Interest: The authors declare no conflict of interest.
References
1. Garami, A.; Pakai, E.; Rumbus, Z.; Solymar, M. The role of PACAP in the regulation of body temperature.
In Pituitary Adenylate Cyclase Activating Polypeptide—PACAP; Reglodi, D., Tamas, A., Eds.; Springer Nature:
New York, NY, USA, 2016; Volume 11, pp. 239–257.
2. Clason, T.A.; Girard, B.M.; May, V.; Parsons, R.L. Activation of MEK/ERK signaling by PACAP in guinea pig
cardiac neurons. J. Mol. Neurosci. 2016, 59, 309–316. [CrossRef] [PubMed]
3. Bardosi, S.; Bardosi, A.; Nagy, Z.; Reglodi, D. Expression of PACAP and PAC1 receptor in normal human
thyroid gland and in thyroid papillary carcinoma. J. Mol. Neurosci. 2016, 60, 171–178. [CrossRef]
4. Juhasz, T.; Szentleleky, E.; Szucs Somogyi, C.S.; Takacs, R.; Dobrosi, N.; Engler, M.; Tamas, A.; Reglodi, D.;
Zakany, R. Pituitary adenylate cyclase activating polypeptide (PACAP) pathway is induced by mechanical
load and reduces the activity of Hedghog signalling in chondrogenic micromass cell cultures. Int. J. Mol. Sci.
2015, 16, 17344–17367. [CrossRef] [PubMed]
Int. J. Mol. Sci. 2017, 18, 675 10 of 12
5. Krajcs, N.; Hernadi, L.; Pirger, Z.S.; Reglodi, D.; Toth, G.; Kiss, T. PACAP modulates acetylcholine-elicited
contractions at nicotinic neuromuscular contacts of the Land snail. J. Mol. Neurosci. 2015, 57, 492–500.
[CrossRef] [PubMed]
6. Somogyvari-Vigh, A.; Reglodi, D. Pituitary adenylate cyclase activating polypeptide: A potential
neuroprotective peptide. Curr. Pharm. Des. 2004, 10, 2861–2889. [CrossRef] [PubMed]
7. Reglodi, D.; Kiss, P.; Lubics, A.; Tamas, A. Review of the protective effects of PACAP in models of
neurodegenerative diseases in vitro and in vivo. Curr. Pharm. Des. 2011, 17, 962–972. [CrossRef] [PubMed]
8. Shioda, S.; Nakamachi, T. PACAP as a neuroprotective factor in ischemic neuronal injuries. Peptides 2015, 72,
202–207. [CrossRef] [PubMed]
9. Tamas, A.; Reglodi, D.; Farkas, O.; Kovesdi, E.; Pal, J.; Povlishock, J.T.; Schwarcz, A.; Czeiter, E.; Szanto, Z.;
Doczi, T.; et al. Effects of PACAP in central and peripheral nerve injuries. Int. J. Mol. Sci. 2012, 13, 8430–8448.
[CrossRef] [PubMed]
10. Tsuchida, M.; Nakamachi, T.; Sugiyama, K.; Tsuchikawa, D.; Watanabe, J.; Hori, M.; Yoshikawa, A.; Imai, N.;
Kagami, N.; Matkovits, A.; et al. PACAP stimulates functional recovery after spinal cord injury through
axonal regeneration. J. Mol. Neurosci. 2014, 54, 380–387. [CrossRef] [PubMed]
11. Tamas, A.; Lubics, A.; Lengvari, I.; Reglodi, D. Protective effects of PACAP in excitotoxic striatal lesion.
Ann. N. Y. Acad. Sci. 2006, 1070, 570–574. [CrossRef] [PubMed]
12. Lamine, A.; Létourneau, M.; Doan, N.D.; Maucotel, J.; Couvineau, A.; Vaudry, H.; Chatenet, D.; Vaudry, D.;
Fournier, A. Characterizations of a synthetic pituitary adenylate cyclase-activating polypeptide analog
displaying potent neuroprotective activity and reduced in vivo cardiovascular side effects in a Parkinson’s
disease model. Neuropharmacology 2016, 108, 440–450. [CrossRef] [PubMed]
13. Reglodi, D.; Renaud, J.; Tamas, A.; Tizabi, Y.; Socías, B.; Del-Bel, E.; Raisman-Vozari, R. Novel tactics for
neuroprotection in Parkinson’s disease: Role of antibiotics, polyphenols and neuropeptides. Prog. Neurobiol.
2015. [CrossRef] [PubMed]
14. Reglodi, D.; Tamas, A.; Lubics, A.; Szalontay, L.; Lengvari, I. Morphological and functional effects of PACAP
in a 6-hydroxydopamine-induced lesion of the substantia nigra in rats. Regul. Pept. 2004, 123, 85–94.
[CrossRef] [PubMed]
15. Njaine, B.; Rocha-Martins, M.; Vieira-Vieira, C.H.; de Melo, L.D.; Linden, R.; Braas, K.; May, V.; Martins, R.A.;
Silveira, M.S. Pleiotropic functions of pituitary adenylyl cyclase-activating polypeptide on retinal ontogenesis:
Involvement of KLF4 in the control of progenitor cell proliferation. J. Mol. Neurosci. 2014, 54, 430–442.
[CrossRef] [PubMed]
16. Atlasz, T.; Szabadfi, K.; Kiss, P.; Racz, B.; Gallyas, F.; Tamas, A.; Gaal, V.; Marton, Z.; Gabriel, R.; Reglodi, D.
Pituitary adenylate cyclase activating polypeptide in the retina: Focus on the retinoprotective effects. Ann. N.
Y. Acad. Sci. 2010, 1200, 128–139. [CrossRef] [PubMed]
17. Atlasz, T.; Vaczy, A.; Werling, D.; Kiss, P.; Tamas, A.; Kovacs, K.; Fabian, E.; Kvarik, T.; Mammel, B.;
Danyadi, B.; et al. Neuroprotective effects of PACAP in the retina. In Pituitary Adenylate Cyclase Activating
Polypeptide—PACAP; Reglodi, D., Tamas, A., Eds.; Springer Nature: New York, NY, USA, 2016; Volume 11,
pp. 501–527.
18. Nakamachi, T.; Matkovits, A.; Seki, T.; Shioda, S. Distribution and protective function of pituitary adenylate
cyclase-activating polypeptide in the retina. Front. Endocrinol. Lausanne 2012, 3, 145.
19. Shioda, S.; Takenoya, F.; Wada, N.; Hirabayashi, T.; Seki, T.; Nakamachi, T. Pleiotropic and retinoprotective
functions of PACAP. Anat. Sci. Int. 2016, 91, 313–324. [CrossRef] [PubMed]
20. Shoge, K.; Mishima, H.K.; Saitoh, T.; Ishihara, K.; Tamura, Y.; Shiomi, H.; Sasa, M. Attenuation by PACAP of
glutamate-induced neurotoxicity in cultured retinal neurons. Brain Res. 1999, 839, 66–73. [CrossRef]
21. Fabian, E.; Reglodi, D.; Mester, L.; Szabo, A.; Szabadfi, K.; Tamas, A.; Toth, G.; Kovacs, K. Effects of PACAP
on intracellular signaling pathways in human retinal pigment epithelial cells exposed to oxidative stress.
J. Mol. Neurosci. 2012, 48, 493–500. [CrossRef] [PubMed]
22. Scuderi, S.; D’Amico, A.G.; Castorina, A.; Imbesi, R.; Carnazza, M.L.; D’Agata, V. Ameliorative effect of
PACAP and VIP against increased permeability in a model of outer blood retinal barrier dysfunction. Peptides
2013, 39, 119–124. [CrossRef] [PubMed]
23. Ding, Y.; Cheng, H.; Yu, R.; Tang, C.; Liu, X.; Chen, J. Effects of cyclopeptide C*HSDGIC* from the cyclization
of PACAP (1–5) on the proliferation and UVB-induced apoptosis of the retinal ganglion cell line RGC-5.
Peptides 2012, 36, 280–285. [CrossRef] [PubMed]
Int. J. Mol. Sci. 2017, 18, 675 11 of 12
24. Kiss, P.; Atlasz, T.; Szabadfi, K.; Horvath, G.; Griecs, M.; Farkas, J.; Matkovits, A.; Toth, G.; Lubics, A.;
Tamas, A.; et al. Comparison between PACAP- and enriched environment-induced retinal protection in
MSG-treated newborn rats. Neurosci. Lett. 2011, 487, 400–405. [CrossRef] [PubMed]
25. Seki, T.; Nakatani, M.; Taki, C.; Shinohara, Y.; Ozawa, M.; Nishimura, S.; Ito, H.; Shioda, S. Neuroprotective
effects of PACAP against kainic acid-induced neurotoxicity in rat retina. Ann. N. Y. Acad. Sci. 2006, 1070,
531–534. [CrossRef] [PubMed]
26. Wada, Y.; Nakamachi, T.; Endo, K.; Seki, T.; Ohtaki, H.; Tsuchikawa, D.; Hori, M.; Tsuchida, M.; Yoshikawa, A.;
Matkovits, A.; et al. PACAP attenuates NMDA-induced retinal damage in association with modulation of
the microglia/macrophage status into an acquired deactivation subtype. J. Mol. Neurosci. 2013, 51, 493–502.
[CrossRef] [PubMed]
27. Seki, T.; Itoh, H.; Nakamachi, T.; Shioda, S. Suppression of ganglion cell death by PACAP following optic
nerve transection in the rat. J. Mol. Neurosci. 2008, 36, 57–60. [CrossRef] [PubMed]
28. Atlasz, T.; Szabadfi, K.; Kiss, P.; Marton, Z.; Griecs, M.; Hamza, L.; Gaal, V.; Biro, Z.S.; Tamas, A.; Hild, G.;
et al. Effects of PACAP in UV-A radiation-induced retinal degeneration models in rats. J. Mol. Neurosci. 2011,
43, 51–57. [CrossRef] [PubMed]
29. D’Amico, A.G.; Maugeri, G.; Reitano, R.; Bucolo, C.; Saccone, S.; Drago, F.; D’Agata, V. PACAP modulates
expression of hypoxia-inducible factors in streptozotocin-induced diabetic rat retina. J. Mol. Neurosci. 2015,
57, 501–509. [CrossRef] [PubMed]
30. Szabadfi, K.; Reglodi, D.; Szabo, A.; Szalontai, B.; Valasek, A.; Setalo, G.Y., Jr.; Kiss, P.; Tamas, A.; Wilhelm, M.;
Gabriel, R. Pituitary adenylate cyclase activating polypeptide, a potential therapeutic agent for diabetic
retinopathy in rats: Focus on the vertical information processing pathway. Neurotox. Res. 2016, 29, 432–446.
[CrossRef] [PubMed]
31. Kvarik, T.; Mammel, B.; Reglodi, D.; Kovacs, K.; Werling, D.; Bede, B.; Vaczy, A.; Fabian, E.; Toth, G.; Kiss, P.;
et al. PACAP is protective in a rat model of retinopathy of prematurity. J. Mol. Neurosci. 2016, 60, 179–185.
[CrossRef] [PubMed]
32. Atlasz, T.; Szabadfi, K.; Kiss, P.; Tamas, A.; Toth, G.; Reglodi, D.; Gabriel, R. Evaluation of the protective
effects of PACAP with cell-specific markers in ischemia-induced retinal degeneration. Brain Res. Bull. 2010,
81, 497–504. [CrossRef] [PubMed]
33. Vaczy, A.; Reglodi, D.; Somoskeoy, T.; Kovacs, K.; Lokos, E.; Szabo, E.; Tamas, A.; Atlasz, T. The protective
role of PAC1-receptor agonist maxadilan in BCCAO-induced retinal degeneration. J. Mol. Neurosci. 2016, 60,
186–194. [CrossRef] [PubMed]
34. Werling, D.; Reglodi, D.; Kiss, P.; Toth, G.; Szabadfi, K.; Tamas, A.; Biro, Z.; Atlasz, T. Investigation of PACAP
fragments and related peptides in chronic retinal hypoperfusion. J. Ophthalmol. 2014, 563812. [CrossRef]
[PubMed]
35. Werling, D.; Reglodi, D.; Banks, W.A.; Salameh, T.S.; Kovacs, K.; Kvarik, T.; Vaczy, A.; Kovacs, L.; Mayer, F.;
Danyadi, B.; et al. Ocular delivery of PACAP1—27 protects the retina from ischemic damage in rodents.
Investig. Ophthalmol. Vis. Sci. 2016, 57, 6683–6691. [CrossRef] [PubMed]
36. Vaudry, D.; Falluel-Morel, A.; Bourgault, S.; Basille, M.; Burel, D.; Wurtz, O.; Fournier, A.; Chow, B.K.;
Hashimoto, H.; Galas, L.; et al. Pituitary adenylate cyclase-activating polypeptide and its receptors: 20 years
after the discovery. Pharmacol. Rev. 2009, 61, 283–357. [CrossRef] [PubMed]
37. Erdling, A.; Sheykhzade, M.; Maddahi, A.; Bari, F.; Edvinsson, L. VIP/PACAP receptors in cerebral arteries
of rat: Characterization, localization and relation to intracellular calcium. Neuropeptides 2013, 47, 85–92.
[CrossRef] [PubMed]
38. Araki, N.; Takagi, K. Relaxant effect of pituitary adenylate cyclase-activating polypeptide on guinea-pig
tracheal smooth muscle. Eur. J. Pharmacol. 1992, 216, 113–117. [CrossRef]
39. Baun, M.; Pedersen, M.H.; Olesen, J.; Jansen-Olesen, I. Dural mast cell degranulation is a putative mechanism
for headache induced by PACAP-38. Cephalalgia 2012, 32, 337–345. [CrossRef] [PubMed]
40. Kantora, O.; Molnar, J.; Arimura, A.; Koves, K. PACAP38 and PACAP27 administered
intracerebroventricularly have an opposite effect on LH secretion. Peptides 2000, 21, 817–820. [CrossRef]
41. Björklund, H.; Bignami, A.; Dahl, D. Immunohistochemical demonstration of glial fibrillary acidic protein in
normal rat Müller glia and retinal astrocytes. Neurosci. Lett. 1985, 54, 363–368. [CrossRef]
42. Wojcieszak, J.; Zawilska, J.B. PACAP38 and PACAP6-38 exert cytotoxic activity against human retinoblastoma
Y79 cells. J. Mol. Neurosci. 2014, 54, 463–468. [CrossRef] [PubMed]
Int. J. Mol. Sci. 2017, 18, 675 12 of 12
43. Atlasz, T.; Szabadfi, K.; Reglodi, D.; Kiss, P.; Tamas, A.; Toth, G.; Molnar, A.; Szabo, A.; Gabriel, R. Effects of
pituitary adenylate cyclase activating polypeptide (PACAP1-38) and its fragments on retinal degeneration
induced by neonatal MSG treatment. Ann. N. Y. Acad. Sci. 2009, 1163, 348–352. [CrossRef] [PubMed]
44. Szabadfi, K.; Atlasz, T.; Kiss, P.; Danyadi, B.; Tamas, A.; Helyes, Z.S.; Hashimoto, H.; Shintani, N.; Baba, A.;
Toth, G.; et al. Mice deficient in pituitary adenylate cyclase activating polypeptide (PACAP) are more
susceptible to retinal ischemic injury in vivo. Neurotox. Res. 2012, 21, 41–48. [CrossRef] [PubMed]
45. Szabadfi, K.; Danyadi, B.; Kiss, P.; Tamas, A.; Fabian, E.; Gabriel, R.; Reglodi, D. Protective effects of
vasoactive intestinal peptide (VIP) in ischemic retinal degeneration. J. Mol. Neurosci. 2012, 48, 501–507.
[CrossRef] [PubMed]
46. Nakamachi, T.; Ohtaki, H.; Seki, T.; Yofu, S.; Kagami, N.; Hashimoto, H.; Shintani, N.; Baba, A.; Mark, L.;
Lanekoff, I.; et al. PACAP suppresses dry eye signs by stimulating tear secretion. Nat. Commun. 2016, 7,
12034. [CrossRef] [PubMed]
47. Ma, Y.; Zhao, S.; Wang, X.; Shen, S.; Ma, M.; Xu, W.; Hong, A. A New Recombinant PACAP-derived peptide
efficiently promotes corneal wound repairing and lacrimal secretion. Investig. Ophthalmol. Vis. Sci. 2015, 56,
4336–4349. [CrossRef] [PubMed]
48. Fukiage, C.; Nakajima, T.; Takayama, Y.; Minagawa, Y.; Shearer, T.R.; Azuma, M. PACAP induces neurite
outgrowth in cultured trigeminal ganglion cells and recovery of corneal sensitivity after flap surgery in
rabbits. Am. J. Ophthalmol. 2007, 143, 255–262. [CrossRef] [PubMed]
49. Racz, B.; Gallyas, F., Jr.; Kiss, P.; Toth, G.; Hegyi, O.; Gasz, B.; Borsiczky, B.; Ferencz, A.; Roth, E.; Tamás, A.;
et al. The neuroprotective effects of PACAP in monosodium glutamate-induced retinal lesion involves
inhibition of proapoptotic signaling pathways. Regul. Pept. 2006, 137, 20–26. [CrossRef] [PubMed]
50. Racz, B.; Gallyas, F., Jr.; Kiss, P.; Tamas, A.; Lubics, A.; Lengvari, I.; Roth, E.; Toth, G.; Hegyi, O.; Verzar, Zs.;
et al. Effects of pituitary adenylate cyclase activating polypeptide (PACAP) on the PKA-Bad-14-3-3 signaling
pathway in glutamate-induced retinal injury in neonatal rats. Neurotox. Res. 2007, 12, 95–104. [CrossRef]
[PubMed]
51. Szabo, A.; Danyadi, B.; Bognar, E.; Szabadfi, K.; Fabian, E.; Kiss, P.; Mester, L.; Manavalan, S.; Atlasz, T.;
Gabriel, R.; et al. Effect of PACAP on MAP kinases, Akt and cytokine expressions in rat retinal hypoperfusion.
Neurosci. Lett. 2012, 523, 93–98. [CrossRef] [PubMed]
52. Cervia, D.; Casini, G. The neuropeptide systems and their potential role in the treatment of mammalian
retinal ischemia: A developing story. Curr. Neuropharmacol. 2013, 11, 95–101. [CrossRef] [PubMed]
53. Reglodi, D.; Tamas, A.; Somogyvari-Vigh, A.; Szanto, Z.; Kertes, E.; Lenard, L.; Arimura, A.; Lengvari, I.
Effects of pretreatment with PACAP on the infarct size and functional outcome in rat permanent focal
cerebral ischemia. Peptides 2002, 23, 2227–2234. [CrossRef]
54. Uchida, D.; Arimura, A.; Somogyvari-Vigh, A.; Shioda, S.; Banks, W.A. Prevention of ischemia-induced
death of hippocampal neurons by pituitary adenylate cyclase activating polypeptide. Brain Res. 1996, 736,
280–286. [CrossRef]
55. Falcone, J.A.; Salameh, T.S.; Yi, X.; Cordy, B.J.; Mortell, W.G.; Kabanov, A.V.; Banks, W.A. Intranasal
administration as a route for drug delivery to the brain: Evidence for a unique pathway for albumin.
J. Pharmacol. Exp. Ther. 2014, 351, 54–60. [CrossRef] [PubMed]
56. Salameh, T.S.; Bullock, K.M.; Hujoel, I.A.; Niehoff, M.L.; Wolden-Hanson, T.; Kim, J.; Morley, J.E.; Farr, S.A.;
Banks, W.A. Central nervous system delivery of intranasal insulin: Mechanisms of uptake and effects on
cognition. J. Alzheimer Dis. 2015, 47, 715–728. [CrossRef] [PubMed]
© 2017 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution
(CC BY) license (http://creativecommons.org/licenses/by/4.0/).
